Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism

“Most bleeding events occurred in women, aligning with prior evidence. These results highlight the importance of tailoring antithrombotic therapy duration to individual factors, such as age, sex and cardiovascular risk profile, balancing ischemic protection against bleeding risk.”

“Long-term data is always important, but I would say in this particular group of patients, which are young patients, it's even more important because this is a population that is going to live for many years after the initial event. I think that it was important to have that data beyond 10 years in terms of safety and efficacy of the implanted device and in fact, it seems to be quite clear. This extends the observations of the randomized trials beyond 10 years and up to 17 years of follow-up, showing that really the rates of recurrent ischemic events are extremely low.”